217302-98-2

Upstream product

• 217302-97-1 dimethyl 7-benzyloxy-3-(4-benzyloxyphenyl)-4-ethylpyrrolo[2,1,5-cd]indolizine-1,2-dicarboxylate 
• 217302-91-5 5-amino-2-propylpyridine 
• 20609-24-9 6-propyl-pyridin-3-ol 
• 4548-45-2 2-chloro-5-nitropyridine 
• 217302-90-4 5-nitro-2-propylpyridine 
• 217302-93-7 5-benzyloxy-2-n-propylpyridine 
• 217302-95-9 6-benzyloxy-2-(4-benzyloxyphenyl)-1-ethylindolizine 

Downstream Products

• 217302-56-2 3-(4-benzyloxyphenyl)-4-ethyl-5-hydroxymethylpyrrolo[2,1,5-cd]indolizine-1,2-dicarboxylic acid 
• 217302-99-3 7-Benzyloxy-3-(4-benzyloxyphenyl)-4-ethylpyrrolo[2,1,5-cd]indolizine-1,2-dicarboxylic acid anhydride 

Relevant academic research and scientific papers

Synthesis and estrogen receptor binding affinities of novel pyrrolo[2,1,5-cd]indolizine derivatives

A series of pyrrolo[2,1,5-cd]indolizine derivatives has been synthesized and evaluated as ligands for the estrogen receptor. Properly substituted mono- and di-hydroxy derivatives showed binding in the low nanomolar range in accordance with their structural resemblance to estrogen. (C) 2000 Elsevier Science Ltd.

Pyrrolo[2,1,5-cd]indolizine derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

The present invention relates to therapeutically active compounds of formula I a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.